GSK has announced a $30 billion investment to expand its U.S. operations over the next five years, marking one of the company’s largest commitments outside the United Kingdom. The plan includes $1.2 billion dedicated to new manufacturing facilities and advancements in artificial intelligence and digital technologies.
The investment will enhance research and development capabilities across GSK’s U.S. network, including sites in Pennsylvania, North Carolina, Maryland, and Montana. In Upper Merion, Pennsylvania, the company plans to begin construction in 2026 on a next-generation biologics flex factory focused on developing treatments for respiratory diseases and certain cancers. The project is expected to create approximately 15,000 new jobs nationwide.
“Today, we are committing to invest at least $30 billion in the United States over the next five years, further bolstering the already strong R&D and supply chain we have in the country,” said GSK CEO Emma Walmsley. “$1.2 billion of today’s announcement includes construction of an additional next-gen biologics ‘flex’ factory, powered by AI, advanced technologies and expert talent to produce transformational new respiratory and cancer medicines for American patients.”
The move strengthens GSK’s position in the U.S., which is expected to become its largest hub for clinical studies and pharmaceutical innovation. It also underscores a growing trend of global biopharma companies expanding domestic manufacturing and R&D capacity to improve supply chain resilience and accelerate drug development.
